Recombinant gamma-interferon as first line therapy for high risk myelodysplastic syndromes. Italian MDS Study Group.

Anna Teresa Maiolo(Policlinico San Matteo Fondazione), E. Polli(University of Milan), Rossella Calori(IRCCS Policlinico San Donato), Agostino Cortelezzi(Istituti di Ricovero e Cura a Carattere Scientifico)

PubMed

July 1, 1990

Cited by 15

Related Papers

Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL)

|Blood|2009|433

Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non–High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial

|Journal of Clinical Oncology|2016|394

Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients

|Blood|2014|373

Angiogenesis in myelodysplastic syndromes

|British Journal of Cancer|1999|272

Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia

|Leukemia|2018|250